Previous Article | Next Article ![]()
Molecular and Cellular Biology, November 2007, p. 7574-7581, Vol. 27, No. 21
0270-7306/07/$08.00+0 doi:10.1128/MCB.00439-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
,
Bénédicte Sammut,1,
Daniel B. Graham,1
Joaquim Chan-Wang,1
Karry L. Brim,1
Alan S. Huett,2
Ana V. Miletic,1
Tracie Kloeppel,1
Aimee Landry,2
Ramnik Xavier,2* and
Wojciech Swat1*
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110,1 Center for Computational and Integrative Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 021152
Received 14 March 2007/ Returned for modification 24 April 2007/ Accepted 10 August 2007
|
|
|---|
|
|
|---|
While the majority of the literature concerning PDZ proteins has focused on their functions in neuronal and epithelial cells (3-5, 7, 15), recent studies have implied broader roles for these proteins in polarity determination in nonclassical synaptic systems, including in the immune synapse (10, 11, 32). For example, a founding member of the MAGUK family, Discs large homolog 1 (DLGH1), has recently been proposed to play a crucial role in regulating TCR signaling and T-cell polarity, along with the LAP family protein Scribble and the CARD family protein CARMA1, as well as several PAR family proteins (2, 12, 16, 23-25, 32, 33). However, the physiological relevance of these interactions is not completely understood. For example, it is unclear if DLGH1 plays an activating or inhibitory function in regulating TCR signaling (25, 32).
DLGH1 contains multiple protein interaction domains characteristic of proteins involved in signal transduction, including three N-terminal PDZ domains, a Src homology 3 domain, an i3 domain, a 4.1-binding domain, and a C-terminal guanylate kinase domain that lacks catalytic activity. Previous reports have shown that DLGH1 is expressed at high levels in developing and mature T cells and, following TCR activation, is recruited to lipid rafts and translocated to the immune synapse, where it can couple the TCR with Lck, Zap70, Vav, WASP, and p38 kinase and may influence signaling specificity (16, 24, 25, 32). However, the exact role of DLGH1 in T cells is unclear, as its downregulation by means of small interfering RNA (siRNA) in T-cell lines has been shown to alternatively attenuate and augment T-cell activation (24, 25, 32).
To gain further insights into the physiological role of DLGH1 in TCR signaling, we generated Dlgh1-deficient mice by gene targeting. Since mice harboring homozygous Dlgh1-null mutations show several developmental abnormalities and die perinatally (17), we used recombination-activating gene 2 (Rag-2)-deficient complementation to generate Dlgh1-deficient T cells. Here, we present biochemical and functional analyses of Dlgh1-deficient T cells which indicate that DLGH1 is dispensable for TCR signaling and for normal thymic development. However, DLGH1 is critical for regulation of T-cell proliferative responses. These results represent the first direct demonstration of a role for a MAGUK protein in lymphocytes using gene-targeted mice and indicate that DLGH1 functions in the negative regulation of T-lymphocyte proliferation, consistent with the role of the fly ortholog of the mammalian DLGH1, Discs large (DLG), which functions as an essential tumor suppressor and an attenuator of cell proliferation in imaginal discs during pupal development.
|
|
|---|
Flow cytometry. Single-cell suspensions were prepared from the spleens, thymus, and lymph nodes and stained with antibodies according to standard protocols. Antibody conjugates against the following markers were used: TCRß, Foxp3, CD2, CD4, CD5, CD8, immunoglobulin D, immunoglobulin M, CD21/35, CD23, CD25, CD44, CD62L, and CD69 (BD Biosciences).
Stimulation and proliferation assays. Lymph node T cells were plated at 1 x 106/ml in complete Dulbecco's modified Eagle's medium-10% fetal bovine serum (FBS). The cells were stimulated with the indicated concentrations of soluble anti-CD3 and, when indicated, anti-CD28 (BD Biosciences) was used at 1 µg/ml. Proliferation assays using [3H]thymidine were performed as previously described (6). Labeling with 1 µM carboxyfluorescein succinimidyl ester (CFSE Invitrogen) was performed on lymph node T cells. Briefly, cells were incubated with CFSE for 30 min at 37°C and then washed in complete medium. Labeled cells were cultured with the indicated stimuli for 72 h. The cells were labeled with 1 µM bromodeoxyuridine (BrdU) (Sigma Aldrich) for 1 h at 37°C. After being surface stained for CD4 and CD8, the cells were fixed with 4% paraformaldehyde, washed with staining buffer, and then frozen at –80°C in 10% FBS-90% dimethyl sulfoxide for at least 1 h. After being thawed, the cells were refixed and then permeabilized in 0.5% saponin-1% FBS/phosphate-buffered saline (PBS). The permeabilized cells were treated with 30 µg DNase I (Sigma Aldrich) for 1 h, washed, and then stained with antibodies against BrdU (Invitrogen), followed by 7-amino-actinomycin D (BD Biosciences).
Ca2+ fluxes. Cells were loaded with Fluo-4-AM (Invitrogen) (3 to 5 µg/ml) for 30 min at 37°C with occasional vortexing. The cells were stained with antibodies against CD4 or CD8, washed, resuspended in complete medium, and then analyzed by flow cytometry. Unstimulated cells were run through the cytometer for 20 seconds to establish a baseline and then stimulated with the indicated concentration of anti-CD3, immediately followed by cross-linking with sheep anti-hamster antibodies (Jackson ImmunoResearch Laboratories). Ca2+ fluxes were measured for an additional 5 min, followed by the addition of ionomycin (0.5 µg/ml) for an additional 1 min.
Cytokine assays. Purified lymph node T lymphocytes (105) were incubated with irradiated splenic cells from C57BL/6 Rag-2–/– mice and anti-CD3 antibodies for 24 h. Supernatant cytokine concentrations were analyzed using Cytometric Bead Array Assays (BD Biosciences) according to the manufacturer's instructions.
Immunoblotting and immunochemistry. Purified T cells were stimulated with anti-CD3, followed by cross-linking with anti-hamster antibodies. The cells were washed with cold PBS and then lysed in cold NP-40 lysis buffer (0.5% NP-40, 50 mM Tris-Cl, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, supplemented with Complete protease inhibitors [Roche] according to the manufacturer's specifications) for 10 min at 4°C. The lysates were cleared by centrifugation at 14,000 x g for 10 min at 4°C. Samples were analyzed by Western blotting according to standard procedures using antibodies against phosphotyrosine (4G10; Upstate Biotechnology), phospho-Akt, phospho-p38, phospho-Erk1/2 (Cell Signaling Technology), and Erk2 (Santa Cruz). For T-cell-conjugate assays, white sulfate latex beads (Interfacial Dynamics) coated with anti-CD3 and anti-CD28 antibodies (10 µg/ml) were incubated with purified T cells at a ratio of 1 bead/cell for 30 min at 37°C. The conjugates were fixed with 4% paraformaldehyde for 10 min and then plated onto poly-L-lysine-coated coverslips. The cells were stained with fluorescently labeled phalloidin and the indicated fluorescent conjugated antibodies and analyzed by confocal microscopy.
Semiquantitative and real-time PCRs. CD8+ T cells were purified from lymph node suspensions using magnetic sorting with anti-CD8 beads (Miltenyi Biotech; (purity, >90%). The cells were stimulated on plates coated with anti-CD3 (1 µg/ml) plus soluble anti-CD28 (1 µg/ml) for 18 h and harvested in Trizol (Invitrogen), and RNA was extracted according to the manufacturer's instructions. The extracted RNA was treated with 10 U RNase-free DNase for 15 min at 37°C. cDNA was generated using avian myeloblastosis virus reverse transcriptase (Promega, Madison, WI) according to the manufacturer's instructions. Semiquantitative PCR was performed on fourfold dilutions of the cDNAs. Real-time PCR was performed using an MX300P cycler (Stratagene).
|
|
|---|
![]() View larger version (19K): [in a new window] |
FIG. 1. Proliferation of Dlgh1–/– T lymphocytes. (A and B) Purifed CD8+ and CD4+ T cells from Rag-2-null mice reconstituted with WT or KO fetal liver cells were stimulated with the indicated concentrations of stimulatory anti-CD3 (µg/ml) with or without the addition of anti-CD28 (1 µg/ml) and analyzed for [3H]thymidine incorporation. Shown are raw cpm values from one experiment, representative of three, all with similar results. The error bars indicate standard deviations. (C and D) Lymph node cells from mice reconstituted with WT or KO fetal liver cells were loaded with CFSE and stimulated with the indicated concentrations of anti-CD3 or anti-CD3 plus anti-CD28 (1 µg/ml). The cells were analyzed 72 h poststimulation. Shown is one representative sample from the indicated CD4+ or CD8+ gate (n > 5), all with similar results. Shown in bar graphs below the histograms is one representative experiment (in which the lymphocytes were stimulated with 0.1 µg/ml anti-CD3) showing the percentage of cells in each generation peak as calculated from the cell counts per peak.
|
![]() View larger version (36K): [in a new window] |
FIG. 2. Lymphocyte development in Rag-2-null mice reconstituted with KO fetal liver cells. Single-cell suspensions of thymocytes, splenocytes, or lymph node cells were counted, stained with the indicated fluorescent-antibody conjugates, and analyzed by flow cytometry as described in Materials and Methods. For analyses of CD44, CD62L, and Foxp3, the populations shown are from the indicated CD4 and CD8 gates. The data shown are from a representative experiment (n > 5).
|
|
View this table: [in a new window] |
TABLE 1. Lymphocyte populations in Rag-2-null mice reconstituted with Dlgh1+/– or Dlgh1–/– fetal liver cellsa
|
As an alternative approach, we also generated and analyzed mice harboring a conditional ("floxed") Dlgh1 allele, in which DLGH1 expression can be ablated in T-lineage cells in the presence of lck-Cre transgenes (see Fig. S2 in the supplemental material). Consistent with the results of analyses of Rag-2/Dlgh1 chimeric mice, mice with conditionally deleted Dlgh1 showed normal development of thymocytes and peripheral T lymphocytes (data not shown; see Fig. S2E and F in the supplemental material).
We also addressed the possibility that DLGH1 may be required for T-cell responses to chemokine gradients, such as stromal cell-derived factor 1
(SDF-1
), which have been implicated in the regulation of normal thymic egress (30). In this context, previous studies implicated Scribble, a DLGH1-related protein, in SDF-1
-mediated migration of T cells (16). To address this issue, we analyzed the migration of T lymphocytes from KO or WT chimeras in response to increasing concentrations of SDF-1
using a transwell assay. We found that SDF-1
-induced migration was indistinguishable between KO and WT T lymphocytes (see Fig. S3 in the supplemental material). These data indicate that in primary T lymphocytes, DLGH1 is not required for chemokine-induced migration. Collectively, our results support the hypothesis that Dlgh1 deficiency results in a distortion of TCR signals that leads to an exaggerated proliferative response of T cells in vitro in the absence of major alterations in their development in either primary or secondary lymphoid organs.
Polarization of the actin cytoskeleton and recruitment of polarity and signaling proteins to the immune synapse in the absence of DLGH1. Actin cytoskeletal remodeling is critically important for sustained TCR signaling and activation. The i3 domain of DLGH1 has been shown to interact with proteins of the ezrin-radixin-moesin family, which couple proteins to the actin cytoskeleton. While DLGH1 is found in the immunological synapse following TCR cross-linking, a previous report indicated that cells expressing decreased levels of DLGH1 due to siRNA knockdown have diminished polymerized actin content and disrupted clustering and raft formation following TCR stimulation (25). To determine if DLGH1 is required for actin polymerization in primary Dlgh1-deficient T cells, we analyzed cytoskeletal remodeling and polarization toward a TCR-stimulatory target. Freshly isolated T lymphocytes from KO and WT chimeric mice were incubated with anti-CD3 and anti-CD28 antibody-coated latex beads and then analyzed for actin polymerization (as measured by accumulation of F-actin using phalloidin staining). F-actin accumulations were similar in WT and KO lymphocytes incubated with stimulatory beads (Fig. 3A to C). As expected, few bead-cell conjugates were found in cells incubated with control beads (coated with PBS/bovine serum albumin), nor did these conjugates show F-actin accumulation at the site of conjugation (data not shown).
![]() View larger version (27K): [in a new window] |
FIG. 3. Actin accumulation and recruitment of polarity and signaling proteins to the immune synapse in KO lymphocytes. (A to C) Purifed T cells from chimeric mice were incubated with anti-CD3-coated latex beads for 30 min. The cells were stained with phalloidin and antibodies against Scribble, Vav1, and Zap-70, followed by analysis by confocal microscopy. Shown is one experiment, representative of three. In each experiment, >60 conjugates were analyzed. DIC, differential interference contrast.
|
TCR-induced signaling in Dlgh1-deficient T lymphocytes. DLGH1 contains multiple domains involved in signal transduction and associates with several proteins downstream of TCR activation (10, 11, 16, 24, 25, 32). However, it is unclear whether DLGH1 is required for the regulation of TCR-proximal signaling pathways in primary T cells. Given that DLGH1 is constitutively associated with the Shaker-related potassium channel Kv1.3 in T lymphocytes, which are implicated in the regulation of Ca2+ entry in T lymphocytes (10, 22), we first analyzed Ca2+ mobilization in freshly isolated T cells from KO and WT chimeric mice. Following TCR cross-linking with various doses of anti-TCR antibodies, both KO and WT CD4+ and CD8+ lymph node T cells showed Ca2+ fluxes with indistinguishable kinetics and magnitudes (Fig. 4A and data not shown). These data indicate that in T lymphocytes, DLGH1 is not required for Ca2+ mobilization following TCR cross-linking.
![]() View larger version (27K): [in a new window] |
FIG. 4. Proximal signaling in KO T lymphocytes. (A) Lymph node cells from RAG chimeric mice were loaded with Fluo-4-AM and then stained with antibodies against CD4 (left) or CD8 (right). Cell suspensions were analyzed by flow cytometry for 20 seconds to determine the background and then for an additional 5 min after anti-CD3 (1 µg/ml) stimulation. Ionomycin was added at 5 min to achieve maximal Ca2+ signaling. In each plot, the first arrow indicates the addition of anti-CD3 and the second arrow indicates the addition of ionomycin. (B) Purified T cells from mice reconstituted with WT or KO donor cells were stimulated with 1 µg/ml anti-CD3 for the indicated times. Proteins were detected by Western blotting. Shown is one experiment, representative of three, all with similar results.
|
Cytokine production by Dlgh1-deficient T lymphocytes.
The production of IL-2 is critically dependent on the TCR-induced activation and nuclear translocation of NFAT. Considering that IL-2 production is critical for the proliferation of naïve T lymphocytes and that NFAT activation has been linked to DLGH1 signaling (24, 25, 32), we hypothesized that the hyperproliferation of KO lymphocytes could result from enhanced IL-2 production. However, we found that TCR-induced IL-2 production was indistinguishable between WT and KO CD4+ and CD8+ T lymphocytes (Fig. 5; see Fig. S6 in the supplemental material). Similarly, there were no significant differences in gamma interferon (IFN-
) production between WT and KO T lymphocytes (Fig. 5; see Fig. S6 in the supplemental material). These data show that DLGH1 is not required for the induction of IL-2 or IFN-
in primary T cells and suggest that the perturbations in proliferation observed in KO T cells do not result from deregulated cytokine production.
![]() View larger version (12K): [in a new window] |
FIG. 5. IL-2 and IFN- production from Dlgh1-deficient T lymphocytes. The supernatants from purified T cells stimulated with the indicated concentrations of anti-CD3 antibodies for 24 h were assayed for IL-2 and IFN- production. Shown are the mean concentrations plus standard deviations from five experiments.
|
![]() View larger version (18K): [in a new window] |
FIG. 6. KO CD8+ T-cell entry into S phase following anti-CD3 stimulation. Lymph node T cells from mice reconstituted with WT or KO fetal liver cells were stimulated with the indicated concentrations of stimulatory anti-CD3 and anti-CD28 antibodies (1 µg/ml). The cells were stimulated for 18 h, pulsed with BrdU, and stained with antibodies against BrdU. Shown are the mean values plus standard deviations from five experiments.
|
![]() View larger version (15K): [in a new window] |
FIG. 7. c-myc transcripts in KO CD8+ T cells. (A) Semiquantitative reverse transcription-PCR analysis of c-myc induction in purified CD8+ T cells from WT- or KO-reconstituted mice stimulated for 16 h with 1 µg/ml anti-CD3 and anti-CD28. Fourfold serial dilutions of cDNA from one representative experiment of three is shown. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels were used for normalization of cDNAs. (B) Quantitative RT-PCR analysis of purified CD8+ T cells from WT- or KO-reconstituted mice stimulated for 16 h with 1 µg/ml anti-CD3 and anti-CD28. The data shown are mean values (n = 3) normalized to GAPDH.
|
|
|
|---|
Thus, in contrast to our report in which we concluded that overexpression of DLGH1 attenuates while downregulation of DLGH1 by siRNA enhances TCR signaling (32), Round et al. found that DLGH1 overexpression potentiates NFAT-dependent transcriptional activation while DLGH1 downregulation abrogates TCR-induced F-actin polymerization, lipid raft clustering, and TCR/CD3 capping and leads to defective cytokine production, including IL-2 and IFN-
, due to a block in NFAT-dependent transcriptional activation (24, 25). The latter results are surprising, particularly given our previously published findings, but also in the context of a well-documented propensity of mammalian DLGH proteins, and their Drosophila ortholog, DLG, to function as tumor suppressors and attenuators of cell division, as revealed in various experimental systems to date (reviewed in reference 15). These differences could result from the different experimental models utilized by our group and in previous studies. Our initial studies used siRNA in immortalized T-cell lines (32), while Round et al. used siRNA knockdown of DLGH1 in OT-1 T cells that had been activated and expanded in culture (24, 25). Thus, it is conceivable that DLGH1 functions differently in regard to protein polarity and signaling in antigen-experienced T cells.
In this study, by utilizing Dlgh1-null lymphocytes, we were able to directly analyze the consequences of DLGH1 deficiency in development and activation of primary T cells. Since mice homozygous for the null allele of Dlgh1 exhibit perinatal lethality (17), we utilized Rag-2-deficient complementation with Dlgh1-null fetal liver progenitors and mice with a conditionally targeted Dlgh1 allele to generate T cells lacking DLGH1. Our experiments with these Dlgh1-deficient T cells conclusively establish three major findings. First, we show that DLGH1 is not essential for the differentiation of major thymic or peripheral subsets of
ß lineage T lymphocytes during both fetal and adult development. An important caveat to this conclusion is that we cannot rule out potential effects of TCR repertoire "shifts," which could conceivably compensate for gain or loss of signaling potency by individual TCR heterodimer complexes expressed by developing T cells. To conclusively address this issue, development and selection of Dlgh1-deficient thymocytes will need to be addressed in the context of "fixed" TCR repertoires, for example, by the introduction of conditional/inducible Dlgh1-null alleles into developing T cells that also harbor
ß TCR-transgenes in a positively selecting major histocompatibility complex background in the absence of expression of any endogenous
and ß TCR chain genes. Our second major finding is that DLGH1 is not essential for TCR-induced F-actin accumulation and the recruitment of polarity proteins to the immune synapse, activation of the T-cell cytokines IL-2 and IFN-
, or directional migration toward chemokine gradients. Thirdly, we show that in primary (naïve) T cells, DLGH1 functions as a negative regulator of TCR-induced proliferative responses in vitro. Thus, in the absence of any gross alterations in TCR proximal signal transduction events detectable in T cells lacking DLGH1 protein, DLGH1 appears to be required for normal regulation of TCR signaling outcome and proliferative responses. Alternatively, DLGH1 may function as an adaptor protein regulating signal intensity in other transduction pathways contributing to T-cell proliferation, such as those downstream of cytokine receptors like IL-2 or IL-4. Of note, in our experiments, even substantial downregulation of DLGH1 expression, such as that observed in T cells with a hemizygous Dlgh1-null mutation (Dlgh1+/–) (which equaled or exceeded 50% of total DLGH1 expression), did not lead to any detectable changes in T-cell responses to TCR stimulation. Thus, our experiments show no evidence of DLGH1 haploinsufficiency in developing and mature T cells. We note however, that Dlgh1 gene-deficient T cells may conceivably undergo an in vivo selection process and/or acquire some changes in their TCR signaling apparatus that may compensate for the gain or loss of TCR signaling potency during the course of their development. Also, a compensatory mechanism(s) must exist in vivo for the regulation of T-cell proliferation, as Dlgh1-deficient chimeras do not develop lymphoadenopathy, do not show any lymphoproliferative disorder, and can produce T-dependent humoral responses that appear similar to normal ones (data not shown).
Our studies suggest that DLGH1 is required for proper regulation of c-myc expression in primary T cells. Numerous previous studies have identified c-myc as a master regulator of a transcriptional program linking extracellular signals to cell cycle progression and cell division in a variety of cell types, including T cells (9, 31). These results are intriguing, as DLGH1 could potentially regulate c-myc via a pathway involving GSK3ß and ß-catenin (5, 20). However, at present we do not understand the exact mechanism that may underlie any such potential roles for DLGH1 in these signaling pathways in T cells, as our experiments to directly address the requirement for DLGH1 in ß-catenin signaling in T cells were inconclusive (data not shown). Nevertheless, whatever the mechanism, enhanced c-myc may underlie the accelerated cell cycle entry and hyperproliferation in Dlgh1–/– T cells. Importantly, while loss of DLGH1 leads to considerable effects on c-myc expression, we note that the expression of other DLGH family members, notably DLGH3, may contribute redundant functions in the absence of DLGH1 in T cells. In this regard, although we did not observe any substantial differences in the expression levels of other DLGH family members in the absence of DLGH1 (data not shown), it is also possible that the expression of other MAGUK family proteins, such as Scribble and Lgl, may provide a basis for partial functional redundancy with DLGH1 in the regulation of TCR-induced events. Genetic deletion of other DLGH family members and members of the related families of other MAGUK proteins, in conjunction with deletion of Dlgh1, will be required to define the limits of any such potential functional redundancies.
We declare no conflict of interest.
Published ahead of print on 27 August 2007. ![]()
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
L.M.S. and B.S. contributed equally to this work. ![]()
|
|
|---|
B kinase into the central immune synapse. J. Exp. Med. 200: 1167-1177.
B transcription factors. Nat. Immunol. 8: 154-161.[CrossRef][Medline]This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»